Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Carolina Lima Resende (SAO PAULO, Brazil), E. Viana Mancuzo (BELO HORIZONTE , Brazil), M. Raquel Soares (SAO PAULO , Brazil), P. Miranda Cavalcante Neto (SAO PAULO , Brazil), M. Auxiliadora Moreira (GOIANIA, Brazil), L. Ferreira Neves Arantes (GOIANIA, Brazil), R. Célia Carlos Tibana (SAO PAULO , Brazil), F. Maciel De Aguiar Baptista (SALVADOR, Brazil), T. Senna Galvão Nonato Alves (SALVADOR, Brazil), K. Mueller Storrer (CURITIBA, Brazil), P. Isolani De Oliveira (SAO PAULO, Brazil), F. Maria Pinheiro Machado Nogueira (SAO PAULO, Brazil), R. Boaventura Martins (SAO PAULO, Brazil), S. Lobo Krupok Matias (SAO PAULO, Brazil), S. Abou El Hosn Cordero Da Silva (SAO PAULO, Brazil), V. El Mir Arida (SAO PAULO, Brazil), A. Bezerra Botelho (SAO PAULO, Brazil), B. Leôncio De Moraes Beraldo (SAO PAULO, Brazil), M. Dornfeld Cunha Castro (SAO PAULO, Brazil), C. Yoshito Fukuda (SAO PAULO, Brazil), M. Tenório Cerezoli (SAO PAULO, Brazil), R. Gomes Ferreira (SAO PAULO, Brazil), I. Missrie (SAO PAULO, Brazil), C. Pereira (SAO PAULO, Brazil). Predictive Findings of Progressive Fibrosing Interstitial Lung Disease (PF-ILD). 2253

Member's Comments

No comment yet.

Related content which might interest you: Modes of Disease Progression in Different Forms of Interstitial Lung Disease with Usual Interstitial Pneumonia Histology in Patients with Idiopathic and Non-idiopathic Etiologies - A Single Center Experience Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside Year: 2019 Assessment of Treatment Response in Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment Year: 2019 Prognostic value of 6-Min Walk Test (6MWT) in Patients with non-Idiopathic Pulmonary Fibrosis Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Development Of A Machine Learning Combination With Deep Learning For Diagnosing Idiopathic Pulmonary Fibrosis In Chronic Interstitial Lung Disease Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 The incidence of Progressive Fibrotic Interstitial Lung Diseases (PFILD) treatable with oral-antifibrotic therapy in a UK Specialist Interstitial Lung Disease clinic. Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Utility of Lung Ultrasound in Interstitial Lung Disease - A Paradigm Shift Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020 A Comparison of Pulmonary Rehabilitation Outcomes in Interstitial Lung Disease and Chronic Obstructive Pulmonary Disease Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases Year: 2019 LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014 Verification of genetic associations with Scleroderma associated Interstitial Lung Disease Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019 Cognitive failure in sarcoidosis Source: International Congress 2014 – Sarcoidosis Year: 2014 Diffuse Pulmonary Non-Amyloid Light-Chain Deposition Disease: Phenotypes and Outcome Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases Year: 2021 Management of spontaneous pneumothorax in patients with or without Birt-Hogg-Dubé syndrome Source: International Congress 2014 – ILDs 1 Year: 2014 Computed Tomography Findings as Determinants of Pulmonary Function Tests in Fibrotic Interstitial Lung Diseases Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 A First-in-Class PRS Inhibitor, DWN12088, as a Novel Therapeutic Agent for Systemic Sclerosis and Associated Interstitial Lung Disease Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases Year: 2021 Clinical Features and Prognosis of Acute exacerbation of Connective Tissue Diseases Associated Pulmonary Fibrosis------ Comparision with Idiopathic Pulmonary Fibrosis Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Unclassifiable Interstitial Lung Disease (ILD). Why? Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Pleural effusion in Niemann Pick Disease - associated Interstitial Lung Disease Source: Virtual Congress 2020 – Interstitial lung diseases Year: 2020 Molecular Markers of Telomere Dysfunction and Senescence are Common Findings in the Usual Interstitial Pneumonia Pattern of Lung Fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Lymphangioleiomyomatosis in TOSCA - TuberOus SClerosis registry to increAse disease awareness Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Risk Factor for Chronic Obstructive Pulmonary Disease in Never-Smoker Patients with Non-Cystic Fibrosis Bronchiectasis Source: International Congress 2019 – Bronchiectasis Year: 2019